Prof. Dr. Adnan AYDINER

Yayın Ağı

Makaleler 184

1. Hormon reseptörü pozitif, HER2 negatif metastatik meme kanseri tanısıyla ribosiklib veya palbosiklib ile letrozol kombinasyon tedavisi verilen hastalarda HER2-düşük ekspresyonunun önemi

kahraman s., Hizal M., Gumusay O., Basaran G., Seyyar M., Sahin E., et al.

Turkish Journal of Clinics and Laboratory , cilt.16, sa.2, ss.255-262, 2025 (Hakemli Dergi)

2. Clinical factors predicting objective response to bevacizumab-based chemotherapies in advanced and recurrent epithelial ovarian cancer

Khanmammadov N., Dogan I., Okay N. S., KHISHIGSUREN B., AZİZY A., Saip P., et al.

Minerva obstetrics and gynecology , cilt.77, sa.2, ss.112-118, 2025 (ESCI)

3. Rechallenge of trastuzumab-based therapy in HER2-positive breast cancer patients who progressed after lapatinib plus capecitabine

Khanmammadov N., Doǧan I., KHISHIGSUREN B., AZİZY A., Saip P., AYDINER A.

Medicine (United States) , cilt.104, sa.6, 2025 (SCI-Expanded)

4. The efficacy of second-line chemotherapy in the management of classic and iatrogenic Kaposi sarcoma: An analysis of real-world data

Khanmammadov N., Ferhatoglu F., PAKSOY N., Dogan İ., KHISHIGSUREN B., Nizam N., et al.

Medicine (United States) , cilt.104, sa.6, 2025 (SCI-Expanded)

5. Breast Cancer Recurrence in Initially Clinically Node-Positive Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in the NEOSENTITURK-Trials MF18-02/18-03

Cabioglu N., Karanlık H., Igci A., Muslumanoglu M., Gulcelik M. A., Uras C., et al.

ANNALS OF SURGICAL ONCOLOGY , cilt.32, sa.2, ss.952-966, 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

6. Estrogen receptor positivity in stromal cells of the tumor bed predicts the response to neoadjuvant chemotherapy for breast carcinoma

BAYRAM A., Bagbudar S., KARANLIK H., CABIOĞLU N., AYDINER A., ÖNDER S., et al.

BREAST CANCER RESEARCH AND TREATMENT , 2025 (SCI-Expanded)

7. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

Kahraman S., Karakaya S., Kaplan M. A., SEZGİN GÖKSU S., Ozturk A., Isleyen Z. S., et al.

Scientific Reports , cilt.14, sa.1, 2024 (SCI-Expanded)

8. New Emerging Chemokine Receptors: CCR5 or CXCR5 on Tumor Is Associated with Poor Response to Chemotherapy and Poor Prognosis in Locally Advanced Triple-Negative Breast Cancer

Cabioglu N., Onder S., Karatay H., Bayram A., Oner G., Tukenmez M., et al.

Cancers , cilt.16, sa.13, 2024 (SCI-Expanded) Sürdürülebilir Kalkınma

9. Efficacy of Bevacizumab-Based Terapy in Patient With Metastatic or Recurrent Cervical Cancer: Real Life Data

KHANMAMMADOV N., Dogan I., okay n. s., Ugar M., Osmanova N., Saip P., et al.

Selçuk Tıp Dergisi , cilt.40, sa.2, ss.68-73, 2024 (Hakemli Dergi)

10. Comparative analysis of doublet chemotherapy regimens plus bevacizumab in patients with recurrent ovarian cancer

Khanmammadov N., Doǧan I., Okay N. S., AZİZY A., Saip P., AYDINER A.

Medicine (United States) , cilt.103, sa.1, 2024 (SCI-Expanded) Sürdürülebilir Kalkınma

11. Evaluation of the Efficacy of Bevacizumab-based Therapies in Patients with Platinum-Resistant or-Allergic Metastatic Ovarian Cancer

Khanmammadov N., Doğan İ., Okay N. S., YILDIZ A., Khishigsuren B., AZİZY A., et al.

Turk Onkoloji Dergisi , cilt.39, sa.2, ss.176-182, 2024 (ESCI) Sürdürülebilir Kalkınma

12. The Effect of Adjuvant Therapies for Recurrence in Stage I Breast Cancer Patients: A Single Centre Experience

Doğan İ., Khanmammadov N., Aydin E., PAKSOY N., Ferhatoğlu F., AK N., et al.

Turk Onkoloji Dergisi , cilt.39, sa.3, ss.257-264, 2024 (ESCI, Scopus, TRDizin)

13. Outcomes of the patients with metastatic male breast cancer

Dogan I., Khanmammadov N., ÖZKURT S., AYDINER A., Saip P.

Journal of Cancer Research and Therapeutics , cilt.20, sa.1, ss.98-102, 2024 (SCI-Expanded)

14. Efficacy of Intrathecal Therapy In Breast Cancer Patients With Leptomeningeal Metastasis

Khanmammadov N., Dogan I., AHMED M. A., YILDIZ A., Nizam N., KHISHIGSUREN B., et al.

Eastern Journal of Medicine , cilt.29, sa.4, ss.503-508, 2024 (Scopus)

15. Evaluation of immune density, PD-L1, and CXCR4 expressions in metaplastic breast carcinoma to predict potential immunotherapy benefit.

Bagbudar S., KARANLIK H., Cabioglu N., Bayram A., Tükenmez M., AYDINER A., et al.

Medical oncology (Northwood, London, England) , cilt.41, sa.1, ss.18, 2023 (SCI-Expanded) Sürdürülebilir Kalkınma

16. Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression

DOĞAN İ., Aydin E., KHANMAMMADOV N., Paksoy N., Saip P., AYDINER A.

Scientific Reports , cilt.13, sa.1, 2023 (SCI-Expanded) Sürdürülebilir Kalkınma

17. Long-term outcomes and predictors of recurrence in node-negative early stage breast cancer patients

DOĞAN İ., Aydin E., KHANMAMMADOV N., Paksoy N., Ferhatoğlu F., AK N., et al.

Journal of Cancer Research and Clinical Oncology , cilt.149, sa.16, ss.14833-14841, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

18. Efficacy and outcomes of systemic chemotherapy in posttransplant and immunosuppression associated Kaposi sarcoma: Twenty years experience of a tertiary cancer center

Khanmammadov N. A., Paksoy N., DOĞAN İ., Ferhatoğlu F., Saip P., Aydiner A.

Medicine , cilt.102, sa.39, 2023 (SCI-Expanded) Sürdürülebilir Kalkınma

19. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

Hizal M., Bilgin B., Paksoy N., Atci M. M., KAHRAMAN S., Kilickap S., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.149, sa.8, ss.4141-4148, 2023 (SCI-Expanded)

20. Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study

FERHATOĞLU F., ÇAĞATAY T., OKUMUŞ G., AYDINER A., PAKSOY N., VATANSEVER S., et al.

Eurasian Journal of Medical Investigation , cilt.7, sa.2, ss.101-106, 2023 (Hakemli Dergi)

21. Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors

DOĞAN İ., KHANMAMMADOV N., PAKSOY N., VATANSEVER S., SAİP P., AYDINER A.

Eurasian Journal of Pulmonology , cilt.25, sa.1, ss.27-32, 2023 (Hakemli Dergi)

22. Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated with A Combination of Lapatinib and Capecitabine

DOĞAN İ., Paksoy N., AK N., VATANSEVER S., Saip P., AYDINER A.

European Journal of Breast Health , cilt.19, sa.2, ss.128-133, 2023 (Scopus)

23. Outcomes and Prognostic Factors in HER2-Positive Metastatic Breast Cancer Patients Who Had Developed Brain Metastasis in the Treatment Process

Dogan I., Kizildag İ., Özkurt S., Ibis K., Vatansever S., Saip P., et al.

ONCOLOGY , cilt.101, sa.4, ss.262-269, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

24. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Kahraman S., Erul E., Seyyar M., GÜMÜŞAY Ö., Bayram E., Demirel B. C., et al.

Future oncology (London, England) , cilt.19, sa.10, ss.727-736, 2023 (SCI-Expanded) Sürdürülebilir Kalkınma

25. Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group

DOĞAN İ., AKSOY S., Cakar B., BAŞARAN G., Ercelep O., Molinas Mandel N., et al.

Cancers , cilt.15, sa.6, 2023 (SCI-Expanded)

26. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Karacin C., Oksuzoglu B., Demirci A., KESKİNKILIÇ M., Baytemür N. K., Yılmaz F., et al.

BMC cancer , cilt.23, sa.1, ss.136, 2023 (SCI-Expanded)

27. Weekly paclitaxel treatment in the first-line therapy of classic Kaposi sarcoma: A real-life study

Paksoy N., KHANMAMMADOV N., DOĞAN İ., Ferhatoǧlu F., AHMED M. A., Karaman S., et al.

Medicine (Spain) , cilt.102, sa.5, 2023 (Scopus) Sürdürülebilir Kalkınma

28. Diverging prognostic effects of CD155 and CD73 expressions in locally advanced triple-negative breast cancer

CABIOĞLU N., BAYRAM A., EMİROĞLU S., ÖNDER S., Karatay H., Oner G., et al.

FRONTIERS IN ONCOLOGY , cilt.13, 2023 (SCI-Expanded)

29. Clinicopathologic characteristics and prognostic factors in patients with male breast cancer: A single tertiary center experience

Dogan I., AYDIN E., AK N., ÖZKURT S., İBİŞ K., ŞÜKRÜOĞLU ERDOĞAN Ö., et al.

Journal of Cancer Research and Therapeutics , cilt.19, sa.7, ss.1887-1892, 2023 (SCI-Expanded, Scopus)

30. Immunotherapy for Lung Cancer

Karadurmuş N., AKYÜREK N., AYDINER A., SAVAŞ R., SÖNMEZ Ö., ŞENDUR M. A. N., et al.

Journal of Oncological Science , cilt.9, sa.2, ss.97-111, 2023 (Scopus)

31. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

Gurbuz M., Kutlu Y., AKKUŞ E., KÖKSOY E. B., Kose N., Oven B. B., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.148, sa.12, ss.3547-3555, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma

32. Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study

PAKSOY N., KHANMAMMADOV N., DOĞAN İ., FERHATOĞLU F., YILDIZ A., AK N., et al.

Medicine (United States) , cilt.101, sa.45, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma

33. Abbreviated and Standard Breast MRI in Neoadjuvant Chemotherapy Response Evaluation: A Comparative Study

Yirgin İ., Engin G., Yildiz Ş., Aydin E. C., Karanlik H., Cabioglu N., et al.

CURRENT MEDICAL IMAGING , cilt.18, sa.10, ss.1052-1060, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma

34. Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC

DOĞAN İ., Gurbuz M., Paksoy N., Ferhatoglu F., Vatansever S., Saip P., et al.

MEDICINE , cilt.101, sa.34, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma

35. Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib

DOĞAN İ., Khanmammadov N., Ahmed M. A., Yildiz A., Saip P., Aydiner A., et al.

CLINICAL CANCER INVESTIGATION JOURNAL , sa.4, ss.5-9, 2022 (ESCI)

36. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study

Hizal M., Bilgin B., Paksoy N., Kilickap S., Atci M. M., KAHRAMAN S., et al.

FUTURE ONCOLOGY , cilt.18, ss.2573-2582, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma

37. Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination.

Dogan I., Paksoy N., Ak N., Vatansever S., Saip P., Aydiner A.

JOURNAL OF CLINICAL ONCOLOGY , cilt.40, sa.16, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma

38. Recurrent autoimmune encephalitis related to immune checkpoint inhibitors

Ser M. H., Samanci N. S., Naziye A. K., Aydiner A., Ozkara C.

EPILEPTIC DISORDERS , cilt.24, sa.3, ss.609-613, 2022 (SCI-Expanded)

39. Outcomes and prognostic factors in patients with HER2-positive metastatic breast cancer with brain metastasis.

Dogan I., Yirgin I. K., Ozkurt S., Ibıs K., Vatansever S., Saip P., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.40, sa.16_suppl, ss.14002, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma

40. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

Hizal M., Bilgin B., Paksoy N., Acikgoz O., Sezer A., Gurbuz M., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.148, sa.6, ss.1501-1508, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma

41. Crizotinib in Metastatic ALK mutant Non-small Cell Lung Cancer Patients: A Single Centre Experience

DOĞAN İ., Khanmammadov N., Ahmed M. A., Yildiz A., Saip P., Aydiner A., et al.

CLINICAL CANCER INVESTIGATION JOURNAL , sa.3, ss.25-29, 2022 (ESCI)

42. Are false-negative rates of sentinel lymph node biopsy after neoadjuvant chemotherapy really associated with poor prognosis in clinically node-positive disease at diagnosis?

Cabioglu N., Karanlik H., Igci A., Muslumanoglu M., Tukenmez M., Emiroglu S., et al.

ANNALS OF SURGICAL ONCOLOGY , cilt.29, sa.SUPPL 1, ss.310-311, 2022 (SCI-Expanded, Scopus)

43. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study

Cil I., Kucukarda A., Atci M. M., Secmeler S., Paksoy N., Ferhatoglu F., et al.

TUMORI JOURNAL , cilt.108, sa.1, ss.19-25, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma

44. Clinicopathological and Prognostic Features of 67 Cases with Pulmonary Sarcomatoid Carcinoma: An 18-Year Single-Centre Experience

Ferhatoglu F., Amirov F., Ozkan B., Kara M., Toker A., Ak N., et al.

ONCOLOGY RESEARCH AND TREATMENT , sa.11, ss.590-600, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

45. Demonstration of in vivo estrogen receptor status with 16 alpha- [F-18]fluoro-17 beta-oestradiol (FES) PET/CT in a rare case of benign metastasizing leiomyoma

Has Simsek D., Kuyumcu S., Ozkan Z. G., Vuralli Bakkaloglu D., Bayram A., Topuz S., et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.48, sa.12, ss.4101-4102, 2021 (SCI-Expanded)

46. Sentinel Lymph Node Biopsy May Prevent Unnecessary Axillary Dissection in Patients with Inflammatory Breast Cancer Who Respond to Systemic Treatment

Karanlik H., CABIOĞLU N., Oprea A. L., ÖZGÜR İ., AK N., AYDINER A., et al.

BREAST CARE , cilt.16, sa.5, ss.468-474, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

47. Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node positive breast cancer at diagnosis: Turkish Multicentric NEOSENTI-TURK MF-18-02-study

Cabıoğlu N., Karanlık H., Yıldırım N., Müslümanoğlu M., Çakmak Karadeniz G., Trabulus Can D., et al.

EJSO , sa.10, ss.2506-2514, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

48. Nivolumab treatment for metastatic thymic epithelial tumors.

Ak N., Aydiner A.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners , cilt.27, ss.1710-1715, 2021 (SCI-Expanded)

49. Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer center

Ak N., Toker A., Kara M., Ozkan B., Ulker M., Kaba E., et al.

TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY , cilt.29, sa.4, ss.487-495, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

50. Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy

Oner G., Onder S., Karatay H., Ak N., Tukenmez M., Muslumanoglu M., et al.

WORLD JOURNAL OF SURGICAL ONCOLOGY , cilt.19, sa.1, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

51. The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: A Turkish Oncology Group Study

Ak N., Ozkan B., Yenigun M. B., Yilmazbayhan D., Toker A., Ferhatoglu F., et al.

JOURNAL OF BUON , cilt.26, sa.3, ss.819-829, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

52. Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors.

Aydiner A., Dogan I., Khanmammadov N., Saip P., Vatansever S.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.15, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

53. Long-term outcomes and predictors of recurrence in patients with early-stage node negative breast cancer.

Dogan I., Aydin E., Paksoy N., Ferhatoglu F., Ak N., Ibis K., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.15, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

54. TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer

Cabioglu N., Onder S., Oner G., Karatay H., Tukenmez M., Muslumanoglu M., et al.

BMC CANCER , cilt.21, sa.1, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

55. Termination of trastuzumab-based treatment after complete response in HER2-positive metastatic breast cancer

Dogan I., Aydin E., Khanmammadov N., Aydiner A., Saip P.

CANCER RESEARCH , cilt.81, sa.4, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

56. Sentinel lymph node biopsy alone in locally advanced breast cancer after neoadjuvant chemotherapy: Turkish multicentric neosenti-turk MF-18-02-study

Cabioglu N., Karanlik H., Muslumanoglu M., Cakmak G. K., Trablus D. C., Tukenmez M., et al.

CANCER RESEARCH , cilt.81, sa.4, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

57. Outcomes of metastatic male breast cancer

Dogan I., Khanmammadov N., Aydiner A., Saip P.

CANCER RESEARCH , cilt.81, sa.4, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

58. Tim3 expression on tumor infiltrating lymphocytes is associated with poor response to neoadjuvan chemotherapy in patients with locally advanced triple negative breast cancer

Cabioglu N., Onder S., Oner G., Karatay H., Tukenmez M., Muslumanoglu M., et al.

CANCER RESEARCH , cilt.81, sa.4, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

59. Effect of Astragalus Membranaceus on Patients with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study

Ak N., Ciftci R., Cabioglu N., Aydiner A.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.36, sa.2, ss.215-221, 2021 (ESCI) Sürdürülebilir Kalkınma

60. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., et al.

LUNG CANCER , cilt.148, ss.48-54, 2020 (SCI-Expanded)

61. Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial

Demir A., Mandel N. M., PAYDAŞ S., Demir G., ER O., Turhal N. S., et al.

BALKAN MEDICAL JOURNAL , cilt.37, sa.2, ss.104-107, 2020 (SCI-Expanded) Sürdürülebilir Kalkınma

62. Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy

Sari M., Aydiner A.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.16, sa.1, ss.132-138, 2020 (SCI-Expanded) Sürdürülebilir Kalkınma

63. High expression of pdl-1 in patients with triple negative breast cancer with residual tumor burden after neoadjuvant chemotherapy.

Oner G., Önder S., Karatay H., Tükenmez M., Muslumanoglu M., Igci A., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.36, 2018 (SCI-Expanded) Sürdürülebilir Kalkınma

64. Epidermal growth factor receptor (EGFR) exon 20 mutations in EGFR-tyrosine kinase inhibitors (EGFR-TKIs) naive non-small cell lung carcinoma (NSCLC) and response to erlotinib therapy

AYDINER A., Sari M.

JOURNAL OF CLINICAL ONCOLOGY , cilt.36, sa.15, 2018 (SCI-Expanded)

65. Effect of the childhood trauma on the adjustment to cancer in the patients with breast cancer

Guveli H., Guveli M. E., Sen F., Oflaz S., Gurdal N., Tambas M., et al.

BREAST CANCER , cilt.24, sa.4, ss.544-551, 2017 (SCI-Expanded) Sürdürülebilir Kalkınma

66. Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

Sen F., Tambas M., Ozkaya K., Guveli M. E., Ciftci R., Ozkan B., et al.

MEDICINE , cilt.95, sa.30, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma

67. Factors affecting progression-free survival in non-HIV-related Kaposi sarcoma

Sen F., Tambas M., Ciftci R., Toz B., Kilic L., Bozbey H. U., et al.

JOURNAL OF DERMATOLOGICAL TREATMENT , cilt.27, sa.3, ss.275-277, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma

68. Combination of adjuvant chemotherapy and radiotherapy is associated with improved survival at early stage type II endometrial cancer and carcinosarcoma

Sozen H., Ciftci R., Vatansever D., Topuz S., Iyibozkurt A. C., Bozbey H. U., et al.

AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY , cilt.56, sa.2, ss.199-206, 2016 (SCI-Expanded)

69. Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer Survival and Response to Treatment

Aydiner A., Sen F., Tambas M., Ciftci R., Eralp Y., Saip P., et al.

MEDICINE , cilt.94, sa.52, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma

70. Is there any effect of first-day usage of a totally implantable venous access device on complications?

Karanlik H., Odabas H., Yildirim I., Ozgur I., Kilic B., Sen F., et al.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , cilt.20, sa.6, ss.1057-1062, 2015 (SCI-Expanded)

71. Concomitant Chemoradiotherapy with Etoposide & Cisplatin versus Docetaxel & Cisplatin in Locally Advanced Non-Small Cell Lung Cancer

Eralp Y., Sen F., Tambas M., Ozkaya K., Ozkan B., Oral E. N., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.10, sa.9, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma

72. Renin-Angiotensin System Blockers May Prolong Survival of Metastatic Non-Small Cell Lung Cancer Patients Receiving Erlotinib

Aydiner A., Ciftci R., Sen F.

MEDICINE , cilt.94, sa.22, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma

73. Effects of Distant Reiki On Pain, Anxiety and Fatigue in Oncology Patients in Turkey: A Pilot Study.

DEMIR M., Can G., KELAM A., AYDINER A.

Asian Pacific journal of cancer prevention : APJCP , cilt.16, ss.4859-62, 2015 (SCI-Expanded)

74. A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer

Yildiz I., Tas F., Kilic L., Sen F., Saip P., Eralp Y., et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , cilt.72, sa.2, ss.437-444, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

75. A comparison of men and women's experiences of chemotherapy-induced alopecia

Can G., Demir M., Erol O., Aydiner A.

EUROPEAN JOURNAL OF ONCOLOGY NURSING , cilt.17, sa.3, ss.255-260, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

76. Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women

Aydiner A.

BREAST , cilt.22, sa.2, ss.121-129, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

77. Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients

Aydiner A., Kilic L., Yildiz I., Keskin S., Sen F., Kucucuk S., et al.

MEDICAL ONCOLOGY , cilt.30, sa.1, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

78. Clinical Outcomes and Prognostic Factors Associated with the Response to Erlotinib in Non-Small-Cell Lung Cancer Patients with Unknown EGFR Mutational Status

Aydiner A., Yildiz I., Seyidova A.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.14, sa.5, ss.3255-3261, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

79. The efficiency of the acupressure in prevention of the chemotherapy-induced nausea and vomiting

Genc A., Can G., Aydiner A.

SUPPORTIVE CARE IN CANCER , cilt.21, sa.1, ss.253-261, 2013 (SCI-Expanded)

80. Does Beta-blocker Therapy Improve the Survival of Patients with Metastatic Non-small Cell Lung Cancer?

Aydiner A., Ciftci R., Karabulut S., Kilic L.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.14, sa.10, ss.6109-6114, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

81. Effects of alopecia on body image and quality of life of Turkish cancer women with or without headscarf

Erol O., Can G., Aydiner A.

SUPPORTIVE CARE IN CANCER , cilt.20, sa.10, ss.2349-2356, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma

82. Association of clinical and pathological variables with survival in thymoma.

Aydiner A., Toker A., Sen F., Bicakci E., Saglam E. K., Erus S., et al.

Medical oncology (Northwood, London, England) , cilt.29, sa.3, ss.2221-8, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma

83. Taxane-induced nail changes: Predictors and efficacy of the use of frozen gloves and socks in the prevention of nail toxicity

Can G., Aydiner A., Cavdar I.

EUROPEAN JOURNAL OF ONCOLOGY NURSING , cilt.16, sa.3, ss.270-275, 2012 (SCI-Expanded)

84. The roles of surgery and EMA/CO chemotherapy regimen in primary refractory and non-refractory gestational trophoblastic neoplasia

Aydiner A., Keskin S., Berkman S., Bengisu E., Ilhan H. R., Tas F., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.138, sa.6, ss.971-977, 2012 (SCI-Expanded)

85. Complementary and Alternative Therapies Used by Turkish Breast Cancer Patients Undergoing Chemotherapy

Can G., Demir M., Aydiner A.

BREAST CARE , cilt.7, sa.6, ss.471-475, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma

86. Complete Response in a Patient with Granulosa Cell Tumor Treated with a Combination of Leuprolide and Tamoxifen

Keskin S., Bengisu E., Tuzlali S., Aydiner A.

ONKOLOGIE , cilt.35, ss.451-453, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma

87. Weekly docetaxel and cisplatin with concomitant radiotherapy in addition to surgery and/or consolidation chemotherapy in stage III non-small cell lung cancer

Sen F., Saglam E. K., Toker A., Dilege S., Kizir A., Oral E. N., et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , cilt.68, sa.6, ss.1497-1505, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

88. A psychometric validation study of the Quality of Life and FAMCARE scales in Turkish cancer family caregivers

Can G., akın S., Aydiner A., Ozdilli K., Oskay U., durna Z.

QUALITY OF LIFE RESEARCH , cilt.20, sa.8, ss.1319-1329, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

89. Induction Chemotherapy With Triweekly Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy With or Without Surgery in Stage III Non-Small-Cell Lung Cancer: A Phase II Study

Aydiner A., Sen F., SAGLAM E. K., Oral E. N., Eralp Y., Tas F., et al.

CLINICAL LUNG CANCER , cilt.12, sa.5, ss.286-292, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

90. Non-pharmacological interventions used by cancer patients during chemotherapy in Turkey

Can G., Erol O., Aydiner A., Topuz E.

EUROPEAN JOURNAL OF ONCOLOGY NURSING , cilt.15, sa.2, ss.178-184, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

91. Development and validation of the Nightingale Symptom Assessment Scale (N-SAS) and predictors of the quality of life of the cancer patients in Turkey

Can G., Aydiner A.

EUROPEAN JOURNAL OF ONCOLOGY NURSING , cilt.15, sa.1, ss.3-11, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

92. Clinical and Pathological Features of Breast Cancer Associated with the Pathological Complete Response to Anthracycline-Based Neoadjuvant Chemotherapy

Keskin S., Muslumanoglu M., Saip P., Karanlik H., Guveli M., Pehlivan E., et al.

ONCOLOGY , cilt.81, sa.1, ss.30-38, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

93. Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy

Akin S., Can G., Aydiner A., Ozdilli K., Durna Z.

EUROPEAN JOURNAL OF ONCOLOGY NURSING , cilt.14, sa.5, ss.400-409, 2010 (SCI-Expanded) Sürdürülebilir Kalkınma

94. The validity and reliability of the Turkish version of the Quality of Life Index [QLI] (Cancer version)

Can G., Durna Z., Aydiner A.

EUROPEAN JOURNAL OF ONCOLOGY NURSING , cilt.14, sa.4, ss.316-321, 2010 (SCI-Expanded) Sürdürülebilir Kalkınma

95. Preliminary testing of a Turkish version of the Strategies Used by Patients to Promote Health (SUPPH) Scale in a sample of breast cancer patients

Akin S., CAN G., Durna Z., AYDINER A.

Journal of Nursing and Healthcare of Chronic Illness , cilt.1, sa.4, ss.303-310, 2009 (Hakemli Dergi) Sürdürülebilir Kalkınma

96. Quality of life and complementary and alternative medicine use among cancer patients in Turkey

Can G., Erol O., Aydiner A., Topuz E.

EUROPEAN JOURNAL OF ONCOLOGY NURSING , cilt.13, sa.4, ss.287-294, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma

97. The role of third generation agents as an induction treatment in concurrent chemoradiotherapy (CRT) for locally-advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials

Aydiner A., Can G.

JOURNAL OF THORACIC ONCOLOGY , cilt.4, sa.9, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma

98. Immune changes in patients with locally advanced breast cancer receiving neoadjuvant chemotherapy

Cabioǧlu N., Müslümanoǧlu M. E., Tütüncü Y., Adin-Cinar S., Gürel N., KIRAN B., et al.

Turkish Journal of Immunology , cilt.13, sa.1, ss.15-20, 2008 (SCI-Expanded) Sürdürülebilir Kalkınma

99. The quality of life and self-efficacy of Turkish breast cancer patients undergoing chemotherapy

Akin S., Can G., Durna Z., Aydiner A.

EUROPEAN JOURNAL OF ONCOLOGY NURSING , cilt.12, sa.5, ss.449-456, 2008 (SCI-Expanded) Sürdürülebilir Kalkınma

100. Predictive factors for local recurrence after breast conservative surgery following neoadjuvant chemotherapy: Our long-term results Neoadjuvan kemoterapi sonrasi meme koruyucu cerrahide lokal nüksü etkileyen faktörler: Uzun dönem sonuçlarimiz

Cabioǧlu N., Müslümanoǧlu M., Iǧci A., Özçinar B., Özmen V., Daǧoǧlu T., et al.

Turk Onkoloji Dergisi , cilt.23, sa.2, ss.81-90, 2008 (SCI-Expanded)

101. Evaluation of the effect of care given by nursing students on oncology patients' satisfaction

Can G., Akin S., Aydiner A., Ozdilli K., Durna Z.

EUROPEAN JOURNAL OF ONCOLOGY NURSING , cilt.12, sa.4, ss.387-392, 2008 (SCI-Expanded)

102. Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer

Tas F., Guney N., Derin D., Camlica H., Aydiner A., Topuz E.

INVESTIGATIONAL NEW DRUGS , cilt.26, sa.4, ss.363-368, 2008 (SCI-Expanded) Sürdürülebilir Kalkınma

103. Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer

Tas F., Derin D., Guney N., Aydiner A., Topuz E.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , cilt.13, sa.4, ss.330-334, 2008 (SCI-Expanded) Sürdürülebilir Kalkınma

104. Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer

Aydiner A., Tas F.

TRIALS , cilt.9, 2008 (SCI-Expanded) Sürdürülebilir Kalkınma

105. Immune changes in patients with locally advenced breast cancer receiving neoadjuvant chemotherapy.

CABIOĞLU N., MÜSLÜMANOĞLU M. E., Tütüncü Y., ÇINAR S., Gürel N., Kıran B., et al.

Türk İmmünoloji Dergisi , cilt.13, ss.15-20, 2008 (Hakemli Dergi) Sürdürülebilir Kalkınma

106. Evaluation of sexual function of Turkish women with breast cancer receiving systemic treatment

Can G., Oskay U., DURNA Z., Aydiner A., Saip P., Disci R., et al.

ONCOLOGY NURSING FORUM , cilt.35, sa.3, ss.471-476, 2008 (SCI-Expanded) Sürdürülebilir Kalkınma

107. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer

Tas F., Guney N., Derin D., Aydiner A., Topuz E.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , cilt.13, sa.2, ss.156-160, 2008 (SCI-Expanded) Sürdürülebilir Kalkınma

108. TREATMENT MODALITIES OF PHYLLODES TUMORS OF THE BREAST

CABIOĞLU N., Celik T., ÖZMEN V., Igci A., Muslumanoglu M., ÖZÇINAR B., et al.

JOURNAL OF BREAST HEALTH , cilt.4, sa.2, ss.99-104, 2008 (ESCI)

109. Predictive factors for local recurrence after breast conservative surgery following neoadjuvant chemotherapy: our long-term results

CABIOĞLU N., Muslumanoglu M., Igci A., Ozcinar B., Ozmen V., Dagoglu T., et al.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.23, sa.2, ss.81-90, 2008 (ESCI)

110. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer

Derin D., Eralp Y., Ozluk Y., Yavuz E., Guney N., Saip P., et al.

CANCER INVESTIGATION , cilt.26, sa.7, ss.671-679, 2008 (SCI-Expanded) Sürdürülebilir Kalkınma

111. Gemcitabine and cisplatin as neo-adjuvant chemotherapy for non-small cell lung cancer: A phase II study

Aydiner A., Kiyik M., Cikrikcioglu S., Kosar F., Gurses A., Turna A., et al.

LUNG CANCER , cilt.58, sa.2, ss.246-252, 2007 (SCI-Expanded) Sürdürülebilir Kalkınma

112. Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma

Tas F., Derin D., Guney N., Camlica H., Aydiner A., Topuz E.

LUNG CANCER , cilt.57, sa.1, ss.79-83, 2007 (SCI-Expanded) Sürdürülebilir Kalkınma

113. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer

Karagol H., Saip P., Uygun K., Caloglu M., Eralp Y., Tas F., et al.

MEDICAL ONCOLOGY , cilt.24, sa.1, ss.39-43, 2007 (SCI-Expanded) Sürdürülebilir Kalkınma

114. Increased sister chromatid exchange frequency in young women with breast cancer and in their first-degree relatives.

Cefle K., Ucur A., Guney N., Ozturk S., Palanduz S., Tas F., et al.

Cancer genetics and cytogenetics , cilt.171, ss.65-7, 2006 (SCI-Expanded) Sürdürülebilir Kalkınma

115. Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma

Karagol H., Saip P., Uygun K., Kucucuk S., Aydiner A., Topuz E.

MEDICAL ONCOLOGY , cilt.23, sa.4, ss.543-548, 2006 (SCI-Expanded)

116. Induction and concurrent chemotherapy with concomitant boost radiotherapy in non-small cell lung cancer

Oral E. N., AYDINER A., ERALP Y., TOPUZ E.

MEDICAL ONCOLOGY , cilt.22, sa.4, ss.367-374, 2005 (SCI-Expanded) Sürdürülebilir Kalkınma

117. Thymidine labeling index: Prognostic role in breast cancer

Bilir A., Eralp Y., Cabioglu N., Agizhali B., Camlica H., Aydiner A.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.27, sa.4, ss.400-406, 2004 (SCI-Expanded) Sürdürülebilir Kalkınma

118. Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma.

TAS F., Yasasever V., DURANYILDIZ D., CAMLICA H., USTUNER Z., AYDINER A., et al.

American journal of clinical oncology , cilt.27, sa.3, ss.225-8, 2004 (SCI-Expanded)

119. T-cell lymphoblastic lymphoma presenting with a breast mass

Yumuk P., Aydiner A., Topuz E., Cabioglu N., Dogan O.

LEUKEMIA & LYMPHOMA , cilt.45, sa.4, ss.833-836, 2004 (SCI-Expanded)

120. Assessment of fatigue in and care needs of Turkish women with breast cancer

Can G., Durna Z., Aydiner A.

CANCER NURSING , cilt.27, sa.2, ss.153-161, 2004 (SCI-Expanded) Sürdürülebilir Kalkınma

121. Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer - Consolidative intraperitoneal cisplatin in ovarian cancer

Topuz E., Eralp Y., Saglam S., Saip P., Aydiner A., Berkman S., et al.

GYNECOLOGIC ONCOLOGY , cilt.92, sa.1, ss.147-151, 2004 (SCI-Expanded) Sürdürülebilir Kalkınma

122. Granulosa cell tumor of the ovary: retrospective analysis of 45 cases.

Uygun K., Aydiner A., Saip P., Basaran M., Tas F., Kocak Z., et al.

American journal of clinical oncology , cilt.26, sa.5, ss.517-21, 2003 (SCI-Expanded)

123. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC)

Alici S., Saip P., Eralp Y., Aydiner A., Topuz E.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.26, sa.4, ss.358-362, 2003 (SCI-Expanded)

124. Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix

Eralp Y., Saip P., Sakar B., Kucucuk S., Aydiner A., Dincer M., et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER , cilt.13, sa.4, ss.497-504, 2003 (SCI-Expanded)

125. Combination chemotherapy with docetaxel and irinotecan in metastatic malignant melanoma.

Tas F., Camlica H., Kurul S., Aydiner A., Topuz E.

Clinical oncology (Royal College of Radiologists (Great Britain)) , cilt.15, sa.3, ss.132-5, 2003 (SCI-Expanded)

126. Inflammatory breast cancer: Results of antracycline-based neoadjuvant chemotherapy

Ozmen V., Cabioglu N., Igci A., Dagoglu T., AYDINER A., Kecer M., et al.

Breast Journal , cilt.9, sa.2, ss.79-85, 2003 (SCI-Expanded) Sürdürülebilir Kalkınma

127. Clinical parameters and treatment results in recurrent granulosa cell tumor of the ovary

Uygun K., Aydiner A., Saip P., Kocak Z., Basaran M., Dincer M., et al.

GYNECOLOGIC ONCOLOGY , cilt.88, sa.3, ss.400-403, 2003 (SCI-Expanded)

128. Efficacy of cisplatin and cyclophosphamide combination for recurrent and metastatic carcinoma of the uterine cervix.

Eralp Y., Saip P., Sakar B., Tas F., Aydiner A., Topuz E.

European journal of gynaecological oncology , cilt.24, ss.323-6, 2003 (SCI-Expanded)

129. Resectable thymoma: Treatment outcome and prognostic factors in the late adolescent and adult age group

ERALP Y., AYDINER A., Kizir A., KAYTAN E., ORAL E., TOPUZ E.

CANCER INVESTIGATION , cilt.21, sa.5, ss.737-743, 2003 (SCI-Expanded)

130. Adjuvant intraperitoneal chemotherapy with cisplatinum, mitoxantrone, 5-fluorouracil, and calcium folinate in patients with gastric cancer: a phase II study.

Topuz E., Basaran M., Saip P., Aydiner A., Argon A., Sakar B., et al.

American journal of clinical oncology , cilt.25, sa.6, ss.619-24, 2002 (SCI-Expanded) Sürdürülebilir Kalkınma

131. Anemia in oncology practice: relation to diseases and their therapies.

Tas F., Eralp Y., Basaran M., Sakar B., Alici S., Argon A., et al.

American journal of clinical oncology , cilt.25, sa.4, ss.371-9, 2002 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

132. Clinical characteristics of gestational trophoblastic disease at a single institute

Alici S., Eralp Y., Saip P., Argon A., Basaran M., Topuz E., et al.

TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE , cilt.197, sa.2, ss.95-100, 2002 (SCI-Expanded) Sürdürülebilir Kalkınma

133. Safety of paclitaxel in a patient with ovarian cancer and hyperbilirubinemia due to Rotor's syndrome.

Argon A., Aydiner A., Tas F., Saip P., Topuz E.

Gynecologic oncology , cilt.85, sa.2, ss.362-4, 2002 (SCI-Expanded) Sürdürülebilir Kalkınma

134. Prognostic role of nm23 gene expression in patients with ovarian cancer.

Tas F., Tuzlali S., Aydiner A., Saip P., Salihoglu Y., Iplikci A., et al.

American journal of clinical oncology , cilt.25, sa.2, ss.164-7, 2002 (SCI-Expanded) Sürdürülebilir Kalkınma

135. Acetaminophen modulations of chemotherapy efficacy in MDAH 2774 human endometrioid ovarian cancer cells in vitro

BILIR A., ALTINOZ M., Attar E., ERKAN M., AYDINER A.

NEOPLASMA , cilt.49, sa.1, ss.38-42, 2002 (SCI-Expanded) Sürdürülebilir Kalkınma

136. Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease.

Tas F., Aykan F., Alici S., Kaytan E., Aydiner A., Topuz E.

American journal of clinical oncology , cilt.24, sa.6, ss.547-50, 2001 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

137. Circulating HER-2/NEU levels in patients with melanoma.

Eralp Y., Aydiner A., Toptani S., Tas F., Camlica H., Topuz E.

CLINICAL CANCER RESEARCH , cilt.7, sa.11, 2001 (SCI-Expanded)

138. Thymidine labeling index in epithelial ovarian cancer

Salihoglu Y., Bilir A., Aydiner A., ERKAN M., TUZLALI S., ERALP Y.

INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS , cilt.75, sa.2, ss.171-176, 2001 (SCI-Expanded) Sürdürülebilir Kalkınma

139. Stevens-Johnson syndrome in a patient receiving anticonvulsant therapy during cranial irradiation.

Eralp Y., Aydiner A., Tas F., Saip P., Topuz E.

American journal of clinical oncology , cilt.24, sa.4, ss.347-50, 2001 (SCI-Expanded)

140. Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer.

Tas F., Aydiner A., Demir C., Topuz E.

American journal of clinical oncology , cilt.24, sa.4, ss.376-8, 2001 (SCI-Expanded) Sürdürülebilir Kalkınma

141. Biological considerations in locally advanced breast cancer treated with anthracycline-based neoadjuvant chemotherapy: thymidine labelling index is an independent indicator of clinical outcome

Ozmen V., CABIOGLU N., DOLAY K., BILIR A., KECER M., AYDINER A., et al.

BREAST CANCER RESEARCH AND TREATMENT , cilt.68, sa.2, ss.147-157, 2001 (SCI-Expanded) Sürdürülebilir Kalkınma

142. Measurement of serum CA 19-9 may be more valuable than CEA in prediction of recurrence in patients with gastric cancer.

TAS F., AYKAN F., AYDINER A., Yasasever V., TOPUZ E.

American journal of clinical oncology , cilt.24, sa.2, ss.148-9, 2001 (SCI-Expanded) Sürdürülebilir Kalkınma

143. The efficacy of combination chemotherapy including intraperitoneal cisplatinum and mitoxantrone with intravenous ifosfamide in patients with FIGO stage I C ovarian carcinoma.

Topuz E., Eralp Y., Saip P., Aydiner A., Taş F., Saliho Y., et al.

European journal of gynaecological oncology , cilt.22, ss.70-3, 2001 (SCI-Expanded)

144. Autophagy and nuclear changes in FM3A breast tumor cells after epirubicin, medroxyprogesterone and tamoxifen treatment in vitro

BILIR A., ALTINOZ M., ERKAN M., Ozmen V., AYDINER A.

PATHOBIOLOGY , cilt.69, sa.3, ss.120-126, 2001 (SCI-Expanded) Sürdürülebilir Kalkınma

145. The role of chemotherapy in malignant mixed mullerian tumors of the female genital tract.

Topuz E., Eralp Y., Aydiner A., Saip P., Taş F., Yavuz E., et al.

European journal of gynaecological oncology , cilt.22, ss.469-72, 2001 (SCI-Expanded)

146. 5-fluorouracil-induced balanitis in a patient with oesophageal carcinoma.

Tas F., Basaran M., Aydiner A., Eralp Y., Topuz E.

Clinical oncology (Royal College of Radiologists (Great Britain)) , cilt.13, sa.3, ss.170-1, 2001 (SCI-Expanded)

147. Hypertrophic osteoarthropathy associated with docetaxel treatment.

Tas F., Aydiner A., Tenekeci N., Karadeniz A. N., Sakar B., Topuz E.

Clinical oncology (Royal College of Radiologists (Great Britain)) , cilt.13, sa.2, ss.145-6, 2001 (SCI-Expanded)

148. The efficacy of combination chemotherapy including intraperitoneal cisplatinum and mitoxantrone with intravenous ifosfamide in patients with FIGO stage IC ovarian carcinoma

Topuz E., Eralp Y., Saip P., Aydiner A., Tas F., Salihoglu Y., et al.

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY , cilt.22, sa.1, ss.70-73, 2001 (SCI-Expanded) Sürdürülebilir Kalkınma

149. Clinical usefulness of serum assays of carcinoembryonic antigen and beta 2-microglobulin in the diagnosis and discrimination of metastasis of lung cancer

Taş F., Aydıner A., Yasasever V., Dişçi R., Topuz E.

Turkish Journal of Cancer , cilt.30, ss.148-154, 2000 (Scopus) Sürdürülebilir Kalkınma

150. Angiogenesis and p53 protein expression in breast cancer - Prognostic roles and interrelationships

TAS F., Yavuz E., AYDINER A., SAİP P., DISCI R., IPLIKCI A., et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.23, sa.6, ss.546-553, 2000 (SCI-Expanded) Sürdürülebilir Kalkınma

151. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.

Tas F., Aydiner A., Topuz E., YASASEVER V., Karadeniz A. N., Saip P. M.

Journal of experimental & clinical cancer research : CR , cilt.19, sa.4, ss.477-81, 2000 (SCI-Expanded) Sürdürülebilir Kalkınma

152. Multiple primary neoplasms at a single institution: differences between synchronous and metachronous neoplasms.

Aydiner A., Karadeniz A. N., Uygun K., Tas S., Tas F., Disci R., et al.

American journal of clinical oncology , cilt.23, sa.4, ss.364-70, 2000 (SCI-Expanded) Sürdürülebilir Kalkınma

153. Celsite (R) port and catheter as an intraperitoneal access device in the treatment of ovarian cancer

TOPUZ E., Salihoglu Y., AYDINER A., Saip P. M., TAS F., SOZEN T., et al.

JOURNAL OF SURGICAL ONCOLOGY , cilt.74, sa.3, ss.223-226, 2000 (SCI-Expanded) Sürdürülebilir Kalkınma

154. Celsite port and catheter as an intraperitoneal access device in the treatment of ovarian cancer.

Topuz E., Salihoglu Y., Aydiner A., Saip P., Tas F., Sozen T., et al.

Journal of surgical oncology , cilt.74, ss.223-6, 2000 (SCI-Expanded) Sürdürülebilir Kalkınma

155. The roles of chemotherapy and surgery in gastric carcinoma and the influence of prognostic factors on survival.

Tas F., Aykan N., Aydiner A., Uygun K., Basaran M., Camlica H., et al.

American journal of clinical oncology , cilt.23, sa.1, ss.53-7, 2000 (SCI-Expanded) Sürdürülebilir Kalkınma

156. Chemotherapy in advanced breast carcinoma: Efficacy of primary and secondary or tertiary docetaxel use.

Aydiner A., Topuz E., Argon A., Saip P., Tas F., Eralp Y., et al.

ANNALS OF ONCOLOGY , cilt.11, ss.37, 2000 (SCI-Expanded)

157. The role of chemotherapy in malignant mixed mullerian tumors of the female genital tract.

TOPUZ E., ERALP Y., AYDINER A., Saip P. M., TAS F., YAVUZ E., et al.

ANNALS OF ONCOLOGY , cilt.11, ss.87-88, 2000 (SCI-Expanded)

158. Long term results and prognostic factors of granulosa cell tumors of the ovary.

SAİP P. M., Uygun K., Topuz E., BAŞARAN M., TAŞ F., AYDINER A., et al.

ANNALS OF ONCOLOGY , cilt.11, ss.87, 2000 (SCI-Expanded)

159. Crossover clinical study comparing the pharmacokinetics of etoposide (75 mg) administered as 25-mg capsules three times a day versus once a day.

Aydiner A., Koyuncu H., Tas F., Topuz E., Disci R.

International journal of clinical pharmacology research , cilt.20, ss.21-30, 2000 (SCI-Expanded)

160. Correlations of serum CA125 level and computerized tomography (CT) imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer.

TOPUZ E., AYDINER A., Saip P. M., ERALP Y., TAS F., Salihoglu Y., et al.

European journal of gynaecological oncology , cilt.21, sa.6, ss.599-602, 2000 (SCI-Expanded) Sürdürülebilir Kalkınma

161. Clinical pharmacokinetic comparative crossover study between three times a day and once a day-oral administration of etoposide

AYDINER A., KOYUNCU H., TOPUZ E., Disci R.

EUROPEAN JOURNAL OF CANCER , cilt.35, 1999 (SCI-Expanded)

162. Adjuvant intraperitoneal chemotherapy with cisplatinum, mitoxantrone, 5-fluorouracil and calcium folinate in stage II-III gastric cancer

Topuz E., Aykan F., Basaran M., Uygun K., Tas F., Sakar B., et al.

EUROPEAN JOURNAL OF CANCER , cilt.35, 1999 (SCI-Expanded) Sürdürülebilir Kalkınma

163. Nursing responsibilities in clinical trials in the Istanbul University Oncology Institute and the implementation of education programmes

Topuz E., Aydiner A., Duma Z.

EUROPEAN JOURNAL OF CANCER , cilt.35, 1999 (SCI-Expanded)

164. Factors influencing the distribution of metastases and survival in extensive disease small cell lung cancer.

Tas F., Aydiner A., Topuz E., Camlica H., Saip P., Eralp Y.

Acta oncologica (Stockholm, Sweden) , cilt.38, sa.8, ss.1011-5, 1999 (SCI-Expanded) Sürdürülebilir Kalkınma

165. Response evaluation of bone metastases in breast cancer: Value of magnetic resonance imaging

SAIP P. M., TENEKECI N., AYDINER A., DINCER M., INANC S., DEMIR C., et al.

CANCER INVESTIGATION , cilt.17, sa.8, ss.575-580, 1999 (SCI-Expanded) Sürdürülebilir Kalkınma

166. Prediction of radiological response of bone metastases to therapy by biochemical marker monitoring in patients with breast cancer: A preliminary study

SAIP P. M., YASASEVER V., TENEKECI N., AYDINER A., INANC S., ONAT H., et al.

JOURNAL OF TUMOR MARKER ONCOLOGY , cilt.13, sa.3, ss.45-52, 1998 (SCI-Expanded) Sürdürülebilir Kalkınma

167. Paraneoplastic limbic encephalitis with immature ovarian teratoma - A case report

Aydiner A., Gurvit H., Baral I.

JOURNAL OF NEURO-ONCOLOGY , cilt.37, sa.1, ss.63-66, 1998 (SCI-Expanded) Sürdürülebilir Kalkınma

168. Catheter complications associated with intraperitoneal chemotherapy

TOPUZ E., Saip P. M., AYDINER A., Salihoglu Y., YILMAZ T., TOPUZLU C.

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY , cilt.19, sa.3, ss.275-279, 1998 (SCI-Expanded) Sürdürülebilir Kalkınma

169. Intraperitoneal cisplatin-mitoxantrone and intravenous ifosfamide combination as first-line treatment of ovarian cancer

TOPUZ E., Saip P. M., Aydiner A., Salihoglu Y., BERKMAN S., BENGISU E.

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY , cilt.19, sa.3, ss.265-270, 1998 (SCI-Expanded) Sürdürülebilir Kalkınma

170. Oral etoposide in patients (pts) with Kaposi's sarcoma (KS)

Aydiner A., Tas F., Saip P., Karadeniz A., Demir C., Salepci T., et al.

EUROPEAN JOURNAL OF CANCER , cilt.33, ss.1178, 1997 (SCI-Expanded)

171. The effects of different treatment models on Turkish women with uterine sarcoma

BERRAK E., ASLAY I., OZTURK N., DINCER M., AYDINER A., OZBILEN S., et al.

EUROPEAN JOURNAL OF CANCER , cilt.33, ss.943, 1997 (SCI-Expanded) Sürdürülebilir Kalkınma

172. Oral etoposide in patients with small cell lung cancer

Topuz E., Tas F., Aydiner A., Demir C., Saip P., Salepci T., et al.

EUROPEAN JOURNAL OF CANCER , cilt.33, ss.1072, 1997 (SCI-Expanded) Sürdürülebilir Kalkınma

173. The effect of the interval between surgery and radiotherapy on local control and overall survival in patients with breast cancer

OZSEKER N., ASLAY I., DINCER M., OZBILEN S., AYDINER A., OZTURK N., et al.

EUROPEAN JOURNAL OF CANCER , cilt.33, ss.363, 1997 (SCI-Expanded) Sürdürülebilir Kalkınma

174. Combined effects of epirubicin and tamoxifen on the cell cycle phases in estrogen-receptor-negative Ehrlich ascites tumor cells

Aydiner A., Ridvanogullari M., Anil D., Topuz E., Nurten R., Disci R.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.123, sa.2, ss.113-117, 1997 (SCI-Expanded)

175. Effects of cisplatin on testicular tissue and the Leydig cell-pituitary axis

Aydiner A., Aytekin Y., Topuz E.

ONCOLOGY , cilt.54, sa.1, ss.74-78, 1997 (SCI-Expanded)

176. Intraperitoneal cisplatin - mitoxantrone in ovarian cancer patients with minimal residual disease

TOPUZ E., AYDINER A., SAIP P. M., BENGISU E., BERKMAN S., Disci R.

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY , cilt.18, sa.1, ss.71-75, 1997 (SCI-Expanded) Sürdürülebilir Kalkınma

177. ACUTE MYOCARDIAL-INFARCTION IN MAN TREATED WITH EPIRUBICIN FOR NON-HODGKIN-LYMPHOMA

AYDINER A., BUGRA Z., TOPUZ E., MERIC M.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.18, sa.5, ss.444-448, 1995 (SCI-Expanded)

178. A comparison of body image, self-esteem and social support in total mastectomy and breast-conserving therapy in Turkish women.

YILMAZER N., AYDINER A., OZKAN S., ASLAY I., BILGE N.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer , cilt.2, sa.4, ss.238-41, 1994 (SCI-Expanded) Sürdürülebilir Kalkınma

179. SERUM TUMOR-MARKERS FOR DETECTION OF BONE METASTASIS IN BREAST-CANCER PATIENTS

AYDINER A., TOPUZ E., DISCI R., YASASEVER v., DINCER M., DINCOL K., et al.

ACTA ONCOLOGICA , cilt.33, sa.2, ss.181-186, 1994 (SCI-Expanded) Sürdürülebilir Kalkınma

180. POTENTIATION OF ETOPOSIDE-INDUCED DNA-DAMAGE BY VERAPAMIL IN L-STRAIN CELLS IN-VITRO

RIDVANOGULLARI M., AYDINER A., ANIL D., SAYIN U., DINCOL K., TOPUZ E., et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH , cilt.12, sa.4, ss.255-260, 1993 (SCI-Expanded)

181. THE EFFICACY OF A 5-DRUG ANTIEMETIC COMBINATION DURING CHEMOTHERAPY REGIMENS CONTAINING CISPLATIN OR CYCLOPHOSPHAMIDE DOXORUBICIN

AYDINER A., ONAT H., OZTURK N., AYKAN F., INANC S., TOPUZ E., et al.

JOURNAL OF PAIN AND SYMPTOM MANAGEMENT , cilt.8, sa.3, ss.126-131, 1993 (SCI-Expanded)

182. TESTICULAR GERM-CELL TUMOR WITH GASTRIC METASTASIS

AYDINER A., OLGAC V., DARENDELILER E., OZTURK N., DINCOL K., ERSEVEN G., et al.

ACTA ONCOLOGICA , cilt.32, sa.4, ss.459-460, 1993 (SCI-Expanded)

183. NEOADJUVANT CHEMOTHERAPY AND RADIOTHERAPY IN LOCALLY ADVANCED UNDIFFERENTIATED NASOPHARYNGEAL CARCINOMA

Onat H., Altun M., Bılge N., Karadenız A. N., Erturk N., Aydıner A., et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH , cilt.11, ss.203-206, 1992 (SCI-Expanded)

184. Lokal ileri indiferansiyenazofarenks kanserinde neoadjuvan kemoterapi ve radyoterapi

Onat H., Altun M., Bilge N., Karadeniz A. N., Ertürk N., Aydıner A., et al.

Klinik Gelişim , cilt.4, sa.12, ss.1616-1619, 1991 (Hakemli Dergi) Sürdürülebilir Kalkınma

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 48

1. Investigation of mirna-193b Expression and Stathmin 1 Level in Serum of Patients with Epithelial Ovary Cancer

Örskaya H. H., Minareci Y., Küçükgergin C., Aydin A. F., Salihoğlu M. Y., Sözen H., et al.

XXXIII. WASPaLM World Congress and XXIV. National Clinicial Biochemistry Congress, Antalya, Türkiye, 16 - 20 Ekim 2024, ss.94, (Özet Bildiri)

2. Comparison of bevacizumab plus doublet chemotherapy regimens in patients with metastatic or recurrent ovarian cancer.

Khanmammadov N., DOĞAN İ., Saip P., Aydiner A.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 2 - 06 Haziran 2023, (Özet Bildiri) Sürdürülebilir Kalkınma

3. Safety and survival in adult women with platinum sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program-LynTurk study

Esin E., Ahmed M. A., Yildirim H. C., Mandel N. M., Erdemoglu E., SARI M., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 2 - 06 Haziran 2023, (Özet Bildiri)

4. The Contribution of 18 F-FES PET/CT in Therapy Management of Estrogen Receptor Positive Breast Cancer

Oflas M., Has Şimşek D., Işık E. G., Cabıoğlu N., İbiş K., Aydıner A., et al.

35'th Annual Congress of Nuclear Medicine, Barcelona, İspanya, 15 - 19 Ekim 2022, (Özet Bildiri)

5. Outcomes and prognostic factors in patients with HER2-positive metastatic breast cancer with brain metastasis

Dogan I., Kızıldağ Yırgın İ., Özkurt S., İbiş K., Vatansever S., Saip P. M., et al.

2022 ASCO Annual Meeting , Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2022, ss.14002, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

6. Östrojen Reseptör (ER) Pozitif Meme Kanserinde 18F-FES PET/BT’nin Tedavi Yönetimine Katkısı

Oflas M., Has Şimşek D., Işık E. G., Cabıoğlu N., İbiş K., Aydıner A., et al.

34. Ulusal Nükleer Tıp Kongresi, Antalya, Türkiye, 27 - 31 Mart 2022, ss.51, (Özet Bildiri) Sürdürülebilir Kalkınma

7. Timik Epitelyal Tümörlerde Ga-68 DOTATATE PET/BT Görüntüleme

Civan C., Özkan Z. G., Özkan B., Işık E. G., Has Şimşek D., Aydıner A., et al.

34. ULUSAL NÜKLEER TIP KONGRESI , Antalya, Türkiye, 27 Mart - 31 Mayıs 2022, ss.16, (Özet Bildiri)

8. EGFR mutasyonlu Metastatik Küçük Hücreli Dışı Akciğer Kanserli Hastalarda Erlotinibin Etkinliğinin Değerlendirilmesi.

Doğan İ., Paksoy N., Kızıldağ Yırgın İ., Aydıner A.

Ulusal Akciğer Sağlığı Kongresi 2021, Antalya, Türkiye, 7 - 10 Ekim 2021, ss.187, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

9. Clinicopathologic features and prognostic factors in male breast cancer: A single centre experience

DOĞAN İ., AYDIN E. M., AK N., İBİŞ K., Sukruoglu Ö., Erciyas S., et al.

ESMO Asia Virtual Congress, ELECTR NETWORK, 20 - 22 Kasım 2020, cilt.31, (Özet Bildiri)

10. .Neoadjuvan Kemoterapi Yanıtının Değerlendirilmesinde Kısaltılmış ve Standart Diagnostik Meme MR Protokollerinin Diagnostik Değerlerinin Karşılaştırılması.

KIZILDAĞ YIRGIN İ., YILDIZ Ş., ENGİN G., CABİOĞLU N., KARANLIK H., TÜKENMEZ M., et al.

. 15. Ulusal Meme Hastalıkları Kongresi, Antalya, Türkiye, 17 - 20 Ekim 2019, (Tam Metin Bildiri)

11. Neoadjuvam kemoterapi öncesi biyopsi ile doğrulanmış aksiller metastazı olan hangi hasta grubunda tedavi sonrası aksiller diseksiyon göz ardı edilebilir?

Karanlık H., Özgür İ., Bademler S., Şen F., Eralp Y., Fayda M., et al.

20. Ulusal Cerrahi Kongresi, 2016, Antalya, Türkiye, 13 - 17 Nisan 2016, ss.1, (Tam Metin Bildiri)

12. İleri yaş erken evre meme kanserlerinde lokal anestezi altında meme cerrahisi.

Karanlık H., Özgür İ., Kılıç B., Bademler S., Şen F., Eralp Y., et al.

13. Ulusal Meme Hastalıkları Kongresi, 2015, Antalya, Türkiye, 21 - 25 Ekim 2015, ss.1, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

13. Factors affecting progression free survival in non-HIV related classical Kaposi sarcoma.

Sen F., Tambas M., Ciftci R., Toz B., Kilic L., Bozbey H. U., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) Sürdürülebilir Kalkınma

14. Effect of renin-angiotensin system blockers on survival of metastatic non-small cell lung cancer patients receiving erlotinib.

Aydiner A., Ciftci R., Sen F.

15. Clinical distuingishing characteristics and management of phyllodes tumors of the breast.

Tukenmez M., Kulle C. B., Velidedeoglu M., Agcaoglu O., Parlakgul G., Aydogan F., et al.

16. Investigation of mir-15a/mir-16-1 expression levels in B-cell non-Hodgkin lymphomas.

Yazici H., kılıç S., avşar M., Sukruoglu O., AKDENIZ D., Ekenel M., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri)

17. Clinical significance of serum epithelial cell adhesion molecule (EPCAM) cud vascular cell adhesion molecule-1 (VCAM-1) levels in lung cancer.

KARABULUT S., Tastekin D., CIFTCI R., Tambas M., DAGOGLU N., Guveil M. E., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri) Sürdürülebilir Kalkınma

18. Association of NBS1 expression with improved pathologic complete response rate in HER2-overexpressing breast cancer.

Sen F., Yavuz E., Yegen G., Karanlik H., Tuzlali S., Aydiner A.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri) Sürdürülebilir Kalkınma

19. Clinicopathological characteristics and survival rate in patients with BRCA1/2 linked ovarian cancer in Turkey

KESKİN S., EKENEL M., KILIC S., SUKRUOGLU O., AYDINER A., ERALP Y., et al.

2nd Mediterranean Multidisciplinaty Oncology Forum, İstanbul, Türkiye, 17 - 19 Kasım 2011, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

20. HIV-Negatif Kaposi Sarkomunda Penis ve Skrotum Tutulumu

ŞEN F., Yıldız İ., KARANLIK H., TOZ B., TUNÇER Ş. B., Ünal E., et al.

19.Ulusal Kanser Kongresi, Antalya, Türkiye, 21 - 24 Nisan 2011, ss.618, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

21. HIV-Negatif Kaposi Sarkomlu Hastalarda Serum Human Herpes Virus 8 DNA Pozitiflik Oranı

ŞEN F., TUNÇER Ş. B., YAZICI H., KURUL S., KARANLIK H., AYDINER A.

19.Ulusal Kanser Kongresi, Antalya, Türkiye, 21 - 24 Nisan 2011, ss.311, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

22. Kaposi Sarkomlu Hastalarda E-Cadherin Gen Mutasyonlarının Araştırılması

TUNÇER Ş. B., ŞEN F., kılıç S., KURUL S., AYDINER A., YAZICI H., et al.

19.Ulusal Kanser Kongresi, Antalya, Türkiye, 21 - 24 Nisan 2011, ss.502, (Tam Metin Bildiri)

23. Meme kanseri hastalarında yeniden evrelendirme amaçlı PET-BT'nin rolü

KUYUMCU S., KARAGÖZ F., ŞANLI Y., EKENEL M., YILDIZ İ., KARABULUT S., et al.

19. Ulusal Kanser Kongresi, Antalya, Türkiye, 20 - 24 Nisan 2011, ss.423, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

24. LOKAL İLERİ MEME KANSERİNDE NEOADJUVAN TEDAVİ AMAÇLI ANTRASİKLİN BAZLI KEMOTERAPİ REJİMİ İLE ANTRASİKLİNE EK OLARAK VERİLEN DOSETAKSELLİ TEDAVİ YÖNTEMLERİNİN KARŞILAŞTIRILMASI

Canbay E., Özçınar B., Özmen V., Müslümanoğlu M. E., Eralp Y., Aydıner A., et al.

İSTANBUL MEME KANSERİ KONFERANSI VE ULUSAL MEME KANSERİ KONSENSUS TOPLANTISI 2008, İstanbul, Türkiye, 21 - 25 Ekim 2008, ss.247, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

25. MEMENİN FİLLODES TÜMÖRLERİNDE TEDAVİ YAKLAŞIMLARI

Çelik T., Cabıoğlu N., Özmen V., İğci A., Müslümanoğlu M. E., Özçınar B., et al.

9. ULUSAL MEME HASTALIKLARI KONGRESİ, Ankara, Türkiye, 5 - 09 Eylül 2007, ss.47, (Özet Bildiri)

26. NEOADJUVAN KEMOTERAPİ SONRASI MEME KORUYUCU CERRAHİDE LOKAL NÜKSÜ ETKİLEYEN FAKTÖRLER: UZUN DÖNEM SONUÇLARIMIZ

Cabıoğlu N., Özçınar B., Müslümanoğlu M. E., Özmen V., İğci A., Dağoğlu T., et al.

9. ULUSAL MEME HASTALIKLARI KONGRESİ, Ankara, Türkiye, 5 - 09 Eylül 2007, ss.40, (Özet Bildiri)

27. Epitelyal Over Kanserli Hastalarda Serum Leptin Düzeyinin Ca125 ve Sağkalım ile İlişkisi

YAZAR A., TAŞ F., OĞUZ SOYDİNÇ H., CAMLICA H., ERALP Y., SAİP P., et al.

I.Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 29 Mart - 02 Nisan 2006, ss.1, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

28. İleri Evre Küçük Hücreli Dışı Akciğer Kanserinde Matriks Metalloproteinaz-9 Düzeyinin Tedavi ile Değişiminin Tedaviye Cevap Ve Sağkalım Ile Ilişkisi

YAZAR A., TAŞ F., OĞUZ SOYDİNÇ H., ERTAN E., YASASEVER V., CAMLICA H., et al.

I.Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 29 Mart - 02 Nisan 2006, ss.1, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

29. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer

Karagol H., Saip P., Uygun K., Caloglu M., Eralp Y., Tas F., et al.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.174, (Özet Bildiri) Sürdürülebilir Kalkınma

30. Induction chemotherapy followed by chemoradiotherapy in patients with stage IIIA-B non-small cell lung cancer (NSCLC)

DAĞOĞLU SAKİN R. N., AYDINER A., Sakallioglu B., Ozturk B., Eralp Y., SAİP P. M., et al.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.229, (Özet Bildiri)

31. Serum levels of leptin and proinflammatory cytokinesin advanced stage non-small cell lung cancer.

Topuz E., Tas F., Argon A., Yildiz D., Oguz H., Yasasever V., et al.

41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, Amerika Birleşik Devletleri, 13 - 17 Mayıs 2005, cilt.23, (Özet Bildiri) Sürdürülebilir Kalkınma

32. The combination of gemcitabine and cisplatin as neoadjuvant chemotherapy for early stage non-small cell lung carcinoma (NSCLC): An interim analysis of a phase II trial.

Aydiner A., Kiyik M., Cikrikcioglu S., Kosar F., Gurses A., Turna A., et al.

41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, Amerika Birleşik Devletleri, 13 - 17 Mayıs 2005, cilt.23, (Özet Bildiri)

33. Serum Levels of Leptin and Proinflammatory Cytokines in Advanced Stage Non-small Cell Lung Cancer

TOPUZ E., TAŞ F., ARGON A., DURANYILDIZ D., OĞUZ SOYDİNÇ H., YASASEVER V., et al.

2005 ASCO Annual Meeting, Orlando/Florıda, Amerika Birleşik Devletleri, 12 - 17 Mayıs 2005, ss.1, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

34. Induction chemotherapy with carboplatin and weekly paclitaxel followed by concomitant chemoradiation in locally advanced non-small cell lung cancer.

Aydiner A., Topuz E., Eralp Y., Kaytan E., Oral E., Kizir A.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Haziran 2004, cilt.22, (Özet Bildiri) Sürdürülebilir Kalkınma

35. An atypical presentation of metastatic choriocarcinoma with maxillary sinus and subcutaneous involvement

Alıcı S., Aydıner A., Eralp Y., Bulutlar G., Altun M., Budak R., et al.

9th International Congress on Anti-Cancer Treatment. 2-5 Febr, 1999, Paris, France, Poster No: 16, Paris, Fransa, 2 - 05 Şubat 1999, ss.16, (Özet Bildiri)

36. Alteration in cellular immunity in patients with advanced breast cancer after neoadjuvant chemotherapy.

Müslümanoğlu M., Cabıoğlu N., Deniz G., Tütüncü Y., Çınar S., Polat N. S., et al.

American Society of Clinical Oncology 34th Annual Meeting , California, Amerika Birleşik Devletleri, 16 - 19 Mayıs 1998, ss.618, (Özet Bildiri) Sürdürülebilir Kalkınma

37. Dimethyl sulfoxide increases the antitumor cytotoxicities of 5-fluorouracil and adriamycin on FMA-3 cell line cultures in tumor colony-forming assays

Bilir A., Ozmen V., Cabioglu N., Muslumanoglu M., Bozfakioglu Y., Igci A., et al.

10th International Congress on Senology - Breast Diseases of the Senologic-International-Society, OPORTO, Portekiz, 31 Mayıs - 04 Haziran 1998, ss.605-611, (Tam Metin Bildiri)

38. Oral etoposide in patients (pts) with Kaposi's sarcoma (KS)

AYDINER A., TAS F., SAİP P. M., KARADENİZ A. N., DEMİR C., SALEPÇİ T., et al.

EUROPEAN JOURNAL OF CANCER, Oxford, Birleşik Krallık, 01 Eylül 1997, cilt.33, sa.8, ss.1178, (Özet Bildiri)

39. Oral etoposide in patients with small cell lung cancer

TOPUZ E., TAŞ F., AYDINER A., DEMİR C., SAİP P. M., SALEPÇİ T., et al.

EUROPEAN JOURNAL OF CANCER, Oxford, Birleşik Krallık, 01 Eylül 1997, cilt.33, sa.8, ss.1072, (Özet Bildiri) Sürdürülebilir Kalkınma

40. Dimetil sülfoksit ve antineoplastik kombinasyonların FMA3 hücre kültürlerinde koloni oluşumu üzerine etkileri

BİLİR A., Özmen V., Müslümanoğlu M., İĞCİ A., bozfakioğlu Y., ASLAY I., et al.

IV. Ulusal Meme Hastalıkları Kongresi, İzmir, Türkiye, 1 - 04 Mart 1997, ss.95, (Özet Bildiri)

41. Adenokistik karsinomda sisplatin, epirubisin, fluorourasil (PEF) kombinasyon kemoterapinin etkinliği

İNANÇ S., ONAT H., ALTUN M., AYDINER A., TOPUZ E.

XI. Ulusal Kanser Kongresi, Antalya, Türkiye, 28 Mayıs - 02 Haziran 1995, ss.43, (Tam Metin Bildiri)

42. Cisplatin, Fluorouracil and alpha-interferon for recurrent or metastatic head and neck cancer

Inanç S., Onat H., Aydıner A., Altun M., Oral E. N., Bilge N., et al.

UICC, XVI International Cancer Congress. Oct 30 -Nov 5, 1994 New Delhi, India, New Delhi, Hindistan, 30 Ekim - 05 Kasım 1994, ss.1, (Özet Bildiri) Sürdürülebilir Kalkınma

43. Lokal tedavi sonrası rezidiv, lokal nüks ve uzak metastazı olan baş-boyun kanserli hastalarda tek ajanlı kemoterapi sonuçları

İNANÇ S., ONAT H., AYDINER A., ÖZTÜRK N., AYKAN F., ALTUN M., et al.

IV. Kemoterapi Kongresi, Bursa, Türkiye, 29 - 31 Ekim 1992, ss.31, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

Kitaplar 15

Metrikler

Yayın

247

Yayın (WoS)

187

Yayın (Scopus)

174

Atıf (WoS)

1780

H-İndeks (WoS)

Atıf (Scopus)

1985

H-İndeks (Scopus)

Atıf (Scholar)

1121

H-İndeks (Scholar)

Proje

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler